MOIL Limited announced its April production performance. The company stated that it has begun FY26 on a strong note by achieving its highest-ever April manganese ore production, reinforcing its commitment to operational excellence. 

Best-Ever April Performance in FY26 

MOIL commenced FY26 on a high note with its highest-ever April production of Manganese (Mn) ore, reaching 1.62 lakh tonnes, marking a 1.5% increase over the corresponding period last year. The company also ramped up exploratory core drilling to 11,453 meters, a notable 58% jump year-on-year, underscoring its long-term growth strategy. 

Shri Ajit Kumar Saxena, CMD, MOIL, stated, “MOIL’s April performance sets a positive tone for the year ahead. The organisation remains committed to sustained growth and value creation.” 

Q4 FY25 Performance Highlights 

Earlier this month, the company also declared its financial performance for Q4 and FY25. In the fourth quarter of FY25, MOIL reported a 27% rise in Profit After Tax (PAT) to ₹115.65 crore. The revenue from operations stood at ₹433.40 crore, registering a 4% increase over the corresponding quarter of the previous year, reflecting consistent demand for manganese ore and related products. 

Full-Year FY25 Highlights 

For the entire fiscal year, MOIL delivered a 30% growth in PAT, reaching ₹381.64 crore, while revenue from operations rose to ₹1,584.94 crore, up by 9% year-on-year. Operationally, MOIL produced 18.03 lakh tonnes of Mn ore, a 3% growth, and achieved 15.87 lakh tonnes in ore sales, rising 3.3% over FY24. 

The company also saw a record ferro manganese sales volume of 12,942 MT, marking a 54% increase year-on-year. Exploratory drilling activities for FY25 totaled 1,07,530 meters, showing a 22% growth, reinforcing MOIL’s focus on resource expansion and reserve building. 

Dividend Declaration 

MOIL’s Board of Directors has proposed a final dividend of ₹1.61 per equity share, in addition to the ₹4.02 interim dividend declared earlier, taking the total dividend for FY25 to ₹5.63 per share. 

MOIL Share Price Performance 

On May 5, 2025, MOIL share price opened at ₹340.00, up from its previous close of ₹338.70. At 11:46 AM, the share price of MOIL was trading at ₹334.25, down by 1.31% on the NSE. 

Also Read: NMDC Share Price Rises Following Iron Ore Price Hike & Interim CFO Appointment!

Conclusion 

MOIL’s performance across FY25 and its operational kickoff in FY26 underlines its steady growth trajectory, strategic investments in exploration, and consistent shareholder returns.  

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

State Bank of India (SBI), announced its financial results for the quarter and full year ended March 31, 2025. 

Post the announcement, on May 5, 2025, State Bank of India share price (NSE: SBIN) opened at ₹782.00, down from its previous close of ₹800.00. At 9:35 AM, the share price of SBIN was trading at ₹784.60, down by 1.92% on the NSE. 

Profitability Growth 

SBI reported an operating profit of ₹1,10,579 crore for FY25, registering a 17.89% year-on-year (YoY) growth and crossing the ₹1 lakh crore mark for the first time. For the fourth quarter (Q4FY25), the operating profit stood at ₹31,286 crore, up 8.83% YoY. 

The net profit for FY25 came in at ₹70,901 crore, reflecting a YoY growth of 16.08%, while Q4FY25 net profit stood at ₹18,643 crore. Return on Assets (ROA) improved to 1.10% and Return on Equity (ROE) stood at a healthy 19.87%, indicating improved profitability. 

Net Interest Income (NII) for FY25 rose by 4.43% YoY. 

Advances and Deposit Growth 

SBI’s total advances crossed ₹42 lakh crore in FY25, with a 12.03% YoY growth in the whole bank advances. Domestic advances rose 11.56% YoY, while advances from foreign offices grew by 14.84%. 

Among loan segments, SME advances grew the fastest at 16.86% YoY, crossing the ₹5 lakh crore mark. Agri advances followed with 14.29% YoY growth, while retail personal and corporate advances rose 11.40% and 9.00% YoY, respectively. 

Total deposits grew 9.48% YoY, with CASA deposits up 6.34% YoY. CASA ratio stood at 39.97% as of March 31, 2025. 

Asset Quality and Capital Position 

SBI’s asset quality improved during the year. Gross NPA ratio declined to 1.82%, an improvement of 42 basis points (bps) YoY, while Net NPA ratio improved by 10 bps YoY to 0.47%. 

The Capital Adequacy Ratio (CAR) stood at 14.25%, reflecting the bank’s strong capital base to support future growth. 

Digital Banking and Alternate Channels 

SBI continued its digital transformation, with 64% of savings bank accounts acquired through its YONO platform. Alternate channels contributed ~98.2% of total transactions in FY25, up from ~97.8% in FY24, indicating growing digital adoption. 

Also Read: SBI Plans to Raise ₹25,000 Crore Via QIP/FPO in FY26! 

SBI Declares Final Dividend of ₹15.90 Per Share for FY25 

State Bank of India has announced a final dividend of ₹15.90 per equity share (face value ₹1 each), translating to 1590% of the face value, for the financial year ended March 31, 2025.  

The record date to determine the eligibility of shareholders for this dividend is set as Friday, May 16, 2025. In accordance with Regulation 10(1) of the SBI General Regulations, 1955, the register of members will remain closed from May 17, 2025 (Saturday) to May 19, 2025 (Monday), both days inclusive, for the purpose of dividend distribution. The dividend will be paid on May 30, 2025. 

Conclusion 

SBI posted its performance in FY25, driven by record profitability, improved asset quality, and solid growth in advances. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Avenue Supermarts Limited declared its standalone and consolidated financial results for the quarter and year ended March 31, 2025. 

Post the announcement, on May 5, 2025, Avenue Supermarts share price (NSE: DMART) opened at ₹3,956.00, down from its previous close of ₹4,059.20. At 9:29 AM, the share price of DMART was trading at ₹3,936.00, down by 3.04% on the NSE. 

Standalone Q4FY25 Performance 

Avenue Supermarts Limited, the operator of DMart retail stores, reported standalone revenue of ₹14,462 crore for the quarter ended March 31, 2025, marking a rise from ₹12,393 crore in Q4FY24. EBITDA for the quarter stood at ₹981 crore, slightly up from ₹940 crore in the same period last year. However, EBITDA margin contracted to 6.8%, down from 7.6% in Q4FY24. 

Net profit also showed a marginal increase, rising to ₹620 crore from ₹604 crore in the year-ago quarter. The PAT margin for the quarter declined to 4.3% compared to 4.9% in Q4FY24, indicating some pressure on profitability despite revenue growth. 

Standalone FY25 Highlights 

For the full financial year FY25, Avenue Supermarts posted standalone revenue of ₹57,790 crore, up from ₹49,533 crore in FY24. EBITDA rose to ₹4,543 crore from ₹4,099 crore in the previous year, but the EBITDA margin narrowed to 7.9%, down from 8.3%. 

Net profit for FY25 stood at ₹2,927 crore, compared to ₹2,695 crore in FY24. PAT margin slightly decreased to 5.1% from 5.4%, in line with the decline in operating margins. 

Consolidated Q4FY25 Results 

On a consolidated basis, Q4FY25 revenue came in at ₹14,872 crore, up from ₹12,727 crore in the corresponding quarter last year. EBITDA was ₹955 crore, almost flat compared to ₹944 crore in Q4FY24. The EBITDA margin dropped to 6.4% from 7.4% in the previous year. 

Net profit declined slightly to ₹551 crore from ₹563 crore in Q4FY24, with PAT margin shrinking to 3.7% from 4.4%. 

Consolidated FY25 Overview 

Consolidated revenue for FY25 reached ₹59,358 crore, rising from ₹50,789 crore in FY24. EBITDA grew to ₹4,487 crore from ₹4,104 crore, but EBITDA margin declined to 7.6% versus 8.1% last year. Net profit stood at ₹2,707 crore, up from ₹2,536 crore in FY24. PAT margin fell to 4.6%, compared to 5.0% previously. 

Commenting on the performance of the company Mr. Neville Noronha, CEO & Managing Director, Avenue Supermarts Limited, said, “Overall business continues to be resilient in metro towns. However, we are doing significantly better in nonmetro towns. We are also having relatively better like-for-like growth in metro towns which have significantly lesser DMart Stores density. While overall gross margins in the matured metro towns will remain soft for a certain period of time, our value positioning is well anchored in the minds of the shoppers of DMart Stores.” 

Also Read: Marico Share Price in Focus: Revenue Grew 12% in FY25, Declared Dividend! 

Conclusion 

Avenue Supermarts demonstrated top-line growth in both quarterly and annual results for FY25. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, has made a significant advancement with its biosimilar Yesintek™ (ustekinumab-kfce).  

Yesintek is a biosimilar to Stelara® (ustekinumab) and has now secured market access agreements representing over 100 million lives in the United States.  

These agreements will significantly improve patient access to cost-effective treatments for chronic autoimmune diseases such as Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. 

Indications and FDA Approval 

Several prominent U.S. health plans have included Yesintek in their formularies, starting with Express Scripts, which added Yesintek to its National Preferred Formulary (NPF) effective March 21, 2025.  

Cigna also added Yesintek to its commercial formulary, effective from the same date. UnitedHealthcare will include Yesintek in its various formularies, such as commercial, managed Medicaid, and Medicare plans, starting from May 1, 2025, March 1, 2025, and June 1, 2025, respectively.  

CVS Health and Optum Rx will begin offering Yesintek starting July 1, 2025. In addition, Yesintek has been selected by several other regional health plans, including Navitus, Costco Health Solutions, and MedImpact. 

Yesintek has been FDA-approved since December 2024 for the treatment of chronic autoimmune diseases. It is available in multiple formulations, including 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial. Clinical studies have demonstrated that Yesintek is highly similar to Stelara, with comparable pharmacokinetic, safety, efficacy, and immunogenicity profiles. 

Management Commentary 

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said, “Yesintek™ (Ustekinumabkfce) represents an important milestone for Biocon Biologics, as this is the first product we have launched in the United States as a fully integrated biosimilars company. The strong adoption of Yesintek™ by payors in the U.S. reflects their confidence in our science, supply reliability, and commercial capability. The listing of Yesintek™ on multiple formularies is another validation that payors in the U.S. are committed to broaden access to affordable treatment options.” 

Josh Salsi, Head of North America, Biocon Biologics Inc., stated, “More than 100 million Americans, representing 70%-80% of the commercial market — are now covered for Yesintek™ (ustekinumabkfce) through commercial formularies. This marks a significant step forward in bringing high-quality, affordable biosimilars to patients managing chronic conditions.” 

Also Read: Biocon Board Greenlights Fundraising Plan of Up to ₹4,500 Crore!

Conclusion 

The broad formulary access and the potential for greater patient affordability mark an important step for Biocon Biologics in expanding its biosimilar portfolio, reinforcing its position in the global biosimilars market. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

Oberoi Realty Limited’s Board of Directors has declared and approved an interim dividend of ₹2 per equity share for the financial year ended March 31, 2025.  

On May 2, 2025, Oberoi Realty share price (NSE: OBEROIRLTY) opened at ₹1,629.30 and closed at ₹1,614.10, down by 1.68%. The stock price touched its day’s low at ₹1,592.20.  

Oberoi Realty Dividend Record Date 

The company’s Board of Directors, at its meeting held on April 28, 2025, declared a fourth interim dividend of ₹2 per equity share (representing 20% of the face value of ₹10 each) for the fourth quarter of the financial year ended March 31, 2025. 

The company stated that the record date for determining eligible shareholders is May 5, 2025, and the interim dividend will be disbursed starting from May 26, 2025. 

FY 2025 Financial Highlights 

For the financial year ended March 31, 2025 (FY25), the company reported consolidated revenue of ₹5,474.17 crore, marking an increase from ₹4,818.77 crore in FY24. EBITDA for the year stood at ₹3,290.95 crore, up from ₹2,732.85 crore in the previous fiscal. Profit Before Tax (PBT) rose to ₹2,944.89 crore from ₹2,475.73 crore in FY24, while Profit After Tax (PAT) increased to ₹2,224.05 crore compared to ₹1,925.17 crore in FY24. 

However, for the fourth quarter of FY25, the company witnessed a decline in performance. Consolidated revenue for Q4FY25 stood at ₹1,213.33 crore, down from ₹1,558.56 crore in Q4FY24. EBITDA dropped to ₹681.26 crore from ₹1,032.36 crore in the year-ago quarter. PAT declined to ₹432.50 crore from ₹787.71 crore in the corresponding quarter of the previous year. 

Also Read: PTC India Shares to Trade Ex-Date on May 5: Interim Dividend of ₹5! 

About Oberoi Realty Ltd 

Oberoi Realty Ltd headquartered in Mumbai, is one of India’s leading real estate developers. The company specialises in premium projects across various segments, including residential, commercial office spaces, retail, hospitality, and social infrastructure. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing. 

 

 

 

 

 

 

Long-term stocks are investments held over several years with the aim of meeting future financial goals. In this article, check the best long-term stocks in May 2025 in India, based on 5-yr CAGR and other parameters and also learn who can invest in them. 

Best Long-Term Stocks in May 2025 – Based on 5yr CAGR 

 

Note: The best long-term stocks list provided here is as of May 2, 2025. The stocks are selected from the Nifty 500 stock universe with positive 1-yr returns and are sorted as per their 5-year CAGR. 

Overview of the 5 Best Long-Term Stocks in India for May 2025 

1. Authum Investment & Infrastructure Ltd 

Authum Investment & Infrastructure Limited is engaged in fund-based activities, including investments in shares, securities, and mutual funds, as well as providing loans and advances. For the quarter ended December 31, 2024, the company reported a total income of ₹619.55 crore, a drop from ₹693.62 crore in the same quarter of the previous year. The profit for the period stood at ₹539.41 crore, down from ₹601.36 crore in Q3 FY24.  

Key metrics: 

• ROE: 62.27% 

• ROCE: 36.83% 

2. Lloyds Metals And Energy Ltd 

Lloyds Metals & Energy is into the manufacturing of sponge iron, power generation and mining activities. For Q3 FY25, the company posted a total income of ₹16,932 million, reflecting a decline of 12.0% compared to ₹19,236 million in Q3 FY24. However, PAT showed a rise of 17.4%, reaching ₹3,893 million, up from ₹3,315 million in the same quarter of the previous fiscal year. 

Key metrics: 

• ROCE: 65.16% 

• ROE: 57.28% 

3. PG Electroplast Ltd 

PG Electroplast Limited (PGEL) specialises in Original Design Manufacturing (ODM), Original Equipment Manufacturing (OEM), and Plastic Injection Molding, serving over 50 top Indian and global brands.

For the quarter ending December 31, FY 2025, PGEL reported operating revenues of ₹967.69 crore, marking a year-on-year growth of 81.9%. The company’s net profit for the quarter stood at ₹40.14 crores, an increase of 108.7% compared to ₹19.24 crores in Q3 FY2024. 

Key metrics: 

• ROCE: 16.97% 

• ROE: 18.79% 

4. Transformers and Rectifiers (India) Ltd 

Transformers and Rectifiers (India) Ltd is engaged in the manufacturing of power, furnace and rectifier transformers. For Q3 FY25, the company reported a total income of ₹56,832 lakhs, marking a 53% YoY increase compared to ₹37,102 lakhs in Q3 FY24. PAT stood at ₹5,552 lakhs, a 252% rise from ₹1,576 lakhs in the same quarter last year. 

Key metrics: 

• ROCE: 24.24% 

• ROE: 23.35% 

5. PTC Industries Ltd 

PTC Industries Limited is engaged in the manufacturing of metal components for critical and supercritical applications. In Q3 FY25, the company posted a total income of ₹771.1 million, reflecting a 30.6% YoY growth compared to ₹590.6 million in Q3 FY24. PAT touched ₹142.4 million, a 76.2% YoY rise from ₹80.8 million in Q3 FY24. 

Key metrics: 

• ROCE: 9.22% 

• ROE: 8.87% 

Best Long-Term Stocks in May 2025 – Based on Net Profit Margin 

Note: The best long-term stocks list provided here is as of May 2, 2025. The stocks are selected from the Nifty 500 stock universe, positive 5-year CAGR, and sorted based on net profit margin. 

Best Long-Term Stocks in May 2025 – Based on Return on Investment 

Note: The best long-term stocks list provided here is as of May 2, 2025. The stocks are selected from the Nifty 500 stock universe, positive 5-year CAGR, and sorted based on return on investment. 

Who Can Invest in Long-Term Stocks in India? 

In India, long-term stocks can be a choice for investors who follow a patient and disciplined approach to investing. These individuals usually aim to achieve financial goals such as retirement planning, funding higher education for their children, or accumulating significant wealth over time. By staying invested for several years, investors can tap into the growth potential of these stocks. This approach not only leverages the power of compounding but can also helps avoid the pressure of reacting to daily market fluctuations. 

Also Read: Best Railway Stocks in India for May 2025: Based on 5-Year CAGR!

Conclusion 

Before making long-term stock investments, it’s important to thoroughly assess the company’s financial health, performance, and growth prospects to make sure that they align with your investment goals and risk tolerance. 

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.